Description
The human sarcoma cell line HT 1080 (ECACC Catalogue number 85111505) was transfected with a vector encoding a selectable marker (guanine phosphoribosyltransferase) regulated by alpha interferon to create the 2fTGH cell line, enabling the selection of mutations in genes encoding components of the interferon signalling pathway. Chemical mutagenesis of the parent 2fTGH cell line enabled the isolation of a number of IFNg signalling mutants available from ECACC U2A (12021502), U3A (12021503), U4A (12021504), U4C (12021505), U5A (12021506), U6A (12021507). Each contains a different mutation in the IFN signalling pathway. The 2fTGH panel provides a tool for the in vitro study and comparison of disrupted interferon signalling at multiple points across the IFN pathway. The U6A mutant lacks the STAT2 subunit of the transcription factor interferon (IFN)-stimulated gene factor 3 (ISGF3). The response of U6A cells to IFN-alpha is almost completely defective whereas the response to IFN-gamma is normal.
Adherent Suspension
Adherent
Suggested Medium
DMEM + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Quality Control
Cell lines were tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Shippment
The cells are shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
Our cell products are for research use only. They are not authorized for human, in vitro diagnostic procedures or for therapeutic procedures.
